A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Inclusion Criteria:
Exclusion Criteria:
Gainsville, Florida, United States
Ashville, North Carolina, United States
Capital Federal, CBA, Argentina
Ciudad de Buenos Aires, Argentina
Oulun Yliopisto, Finland
Hyderabaad, India
Guadalajara - Jalisco, Mexico
Monterrey N.L., Mexico
Wellington South, New Zealand
Barrios Altos-Lima, Peru
La Victoria-Lima, Peru
San Isidro-Lima, Peru
Surco-Lima, Peru
Mures, Romania
Yaroslav, Russia
Gauteng, South Africa